Araris Biotech AG

https://www.ararisbiotech.com

Araris Biotech is a leading company pioneering the future of antibody-drug conjugates (ADCs) and redefining the entire paradigm of targeted cancer therapy and beyond. It is a spin-off company of the Paul-Scherrer-Institute (part of ETH domain) in Switzerland, with Dr. Philipp Spycher, Dr. Isabella Attinger-Toller and Dr. Dragan Grabulovski among its founders. Araris’ vision is a world without chemotherapy and its proprietary conjugation and groundbreaking multi-payload technology represents a quantum leap forward in ADC design, enabling the transformation of any antibody into an ADC with the goal of better safety and efficacy. By enabling the attachment of multiple, synergistic cancer-fighting payloads to a single antibody in an efficient one-step process, Araris is creating a new generation of smart missiles that deliver the potency of combination chemotherapy in a targeted fashion in order to tackle the persistent challenges of cancer resistance. Araris’ investors include 4BIO Capital, b2venture, Pureos Bioventures, Redalpine, Schroders Capital, VI Partners, Wille AG, Institute for Follicular Lymphoma Innovation and Samsung Ventures. *

	Start	2019-01-31 established (s-off)
	Group	Otsuka (Group)
	Predecessor	Paul Scherrer Institute (PSI)
	Industry	antibody-drug conjugates (ADC) technology
	Industry 2	AraLinQ™ technology
	Person	Spycher, Philipp (Araris Biotech 201902– CEO + Co-Founder)
	Person 2	Grabulovski, Dragan (Bellevue 202109– Venture Partner at Pureos Bioventures before Covagen CSO + co-founder)

	Region	Zürich ZH
	Country	Switzerland
	Street	11 Riedhofstr.
	City	8804 Au ZH
		Address record changed: 2022-10-04

Basic data	Employees	A: 1 to 10 (2020-07-01)

		* Document for »About Section«: Araris Biotech AG. (3/17/25). "Press Release: Taiho Pharmaceutical to Acquire Next-Generation ADC Drug Discovery Company Araris Biotech".

		Record changed: 2025-03-21

Picture Informa Connect BioProcess Intl Europe 2025 Hamburg Register 650x200px

More documents for Otsuka (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)